Swedbank AB Buys 5,751 Shares of Amgen Inc. (NASDAQ:AMGN)

Swedbank AB lifted its stake in Amgen Inc. (NASDAQ:AMGN) by 1.1% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 538,899 shares of the medical research company’s stock after acquiring an additional 5,751 shares during the quarter. Swedbank AB owned 0.10% of Amgen worth $173,639,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Zhang Financial LLC boosted its holdings in shares of Amgen by 2.0% in the third quarter. Zhang Financial LLC now owns 15,250 shares of the medical research company’s stock worth $4,914,000 after buying an additional 300 shares during the last quarter. Nova R Wealth Inc. boosted its holdings in shares of Amgen by 0.8% in the third quarter. Nova R Wealth Inc. now owns 12,348 shares of the medical research company’s stock worth $3,979,000 after buying an additional 103 shares during the last quarter. Norway Savings Bank boosted its holdings in shares of Amgen by 12.7% in the third quarter. Norway Savings Bank now owns 3,806 shares of the medical research company’s stock worth $1,226,000 after buying an additional 429 shares during the last quarter. Birch Capital Management LLC boosted its holdings in shares of Amgen by 4.6% in the third quarter. Birch Capital Management LLC now owns 22,109 shares of the medical research company’s stock worth $7,124,000 after buying an additional 968 shares during the last quarter. Finally, Occidental Asset Management LLC boosted its holdings in shares of Amgen by 5.7% in the third quarter. Occidental Asset Management LLC now owns 11,899 shares of the medical research company’s stock worth $3,834,000 after buying an additional 645 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

AMGN has been the topic of a number of research reports. Barclays raised their price objective on shares of Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a report on Monday, October 7th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $305.00 price target (down previously from $310.00) on shares of Amgen in a report on Wednesday, August 7th. Bank of America lifted their price target on shares of Amgen from $325.00 to $330.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. Morgan Stanley lowered their price target on shares of Amgen from $310.00 to $303.00 and set an “equal weight” rating on the stock in a report on Thursday, July 11th. Finally, TD Cowen lifted their price target on shares of Amgen from $360.00 to $381.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Amgen has an average rating of “Hold” and a consensus target price of $326.95.

Amgen Trading Down 0.1 %

Shares of NASDAQ AMGN traded down $0.43 during mid-day trading on Tuesday, reaching $324.19. The company had a trading volume of 983,202 shares, compared to its average volume of 2,455,045. The business’s 50-day moving average is $326.05 and its 200-day moving average is $311.20. The company has a current ratio of 1.26, a quick ratio of 0.89 and a debt-to-equity ratio of 9.64. The stock has a market cap of $173.91 billion, a price-to-earnings ratio of 46.37, a price-to-earnings-growth ratio of 2.86 and a beta of 0.61. Amgen Inc. has a 52 week low of $249.70 and a 52 week high of $346.85.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 EPS for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). The company had revenue of $8.39 billion during the quarter, compared to the consensus estimate of $8.35 billion. Amgen had a return on equity of 161.72% and a net margin of 10.12%. The company’s revenue for the quarter was up 20.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $5.00 earnings per share. Equities analysts expect that Amgen Inc. will post 19.49 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, August 6th. Investors of record on Friday, August 16th were paid a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a yield of 2.78%. The ex-dividend date of this dividend was Friday, August 16th. Amgen’s dividend payout ratio (DPR) is presently 128.57%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.